Biochemical markers in the assessment of bone disease

American Journal of Medicine

Volumn 103, Issue 5, 1997, Pages 427-436

  Bikle, Daniel D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN; HYDROXYPROLINE; OSTEOCALCIN; PYRIDINOLINE;

AGING; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE TURNOVER; CHRONIC KIDNEY FAILURE; CUSHING SYNDROME; EARLY DIAGNOSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTHYROIDISM; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; VITAMIN D DEFICIENCY;

NASA DISCIPLINE MUSCULOSKELETAL; NON-NASA CENTER;

BIOLOGICAL MARKERS; BONE DISEASES; BONE RESORPTION; HUMANS; UNITED STATES;

EID: 0030686535     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00137-X     Document Type: Review

References (72)

1. Rauch F, Schonau E, Woitge H, et al. Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol. 1994;102:94-97.
2. Ohishi T, Takahashi M, Kawana K, et al. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. Clin Invest Med. 1993;16:319-325.
3. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr. 1992;151:764-768.
4. Bouillon R, Bex M, Van Herck E, et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab. 1995;80:1194-1202.
5. Sowers M, Eyre D, Hollis BW, et al. Biochemical markers of bone turnover in lactating and nonlactating postpartum women. J Clin Endocrinol Metab. 1995;80:2210-2216.
6. Gallacher SJ, Fraser WD, Owens OJ, et al. Changes in calciotrophic hormones and biochemical markers of bone turnover in normal human pregnancy. Eur J Endocrinol. 1994;131:369-374.
7. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab. 1995;80:2447-2450.
8. Seibel MJ, Woitge H, Scheidt-Nave C, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res. 1994;9:1433-1440.
9. Garnero P, Gineyts E, Arbault P, et al. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res. 1995;10:641-649.
10. Bonde M, Qvist P, Fledelius C, et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab. 1995;80:864-868.
11. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab. 1994;79:780-785.
12. Riis BJ. Biochemical markers of bone turnover. II. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;95:17S-21S.
13. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990;8:87-96.
14. Arbault P, Grimaux M, Pradet V, et al. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone. 1995;16:461-467.
15. Resch H, Pietschmann P, Kudlacek S, et al. Influence of sex and age on biochemical bone metabolism parameters. Miner Electrolyte Metab. 1994;20:117-121.
16. Garnero P, Sornay-Rendu E, Chapuy M, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337-349.
17. Sone T, Miyake M, Takeda N, Fukunaga M. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age-and sex-related changes and reference limits. Bone. 1995;17:335-339.
18. Yoshimura N, Hashimoto T, Kasamatsu T, et al. Bone metabolic marker levels in residents of a rural community in Japan. J Bone Miner Metab. 1996;14:39-42.
19. Wishart JM, Need AG, Horowitz M, et al. Effect of age on bone density and bone turnover in men. Clin Endocrinol (Oxf). 1995;42:141-146.
20. Egger CD, Muhlbauer RC, Felix R, et al. Evaluation of urinary pyridinium crosslink excretion as a marker of bone resorption in the rat. J Bone Miner Res. 1994;9:1211-1219.
21. Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocrin Rev. 1993;14:424-442.
22. Alvarez L, Guanabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res. 1995;10:458-465.
23. Demiaux B, Arlot ME, Chapuy MC, et al. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab. 1992;74:1146-1151.
24. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
25. Sairanen S, Tahtela R, Laitinen K, et al. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. Calcif Tissue Int. 1994;55:349-352.
26. Nielsen HK. Circadian and circatrigintan changes in osteoblastic activity assessed by serum osteocalcin. Physiological and methodological aspects. Dan Med Bull. 1994;41:216-227.
27. Nielsen HK, Brixen K, Bouillon R, Mosekilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab. 1990;70:1431-1437.
28. Price PA, Williamson MK, Lothringer JW. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981;256:12760-12766.
29. Charles P, Hasling C, Risteli L, et al. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int. 1992;51:406-411.
30. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 1993;77:1046-1053.
31. Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am. 1990;19: 1-18.
32. Delmas PD. Biochemical markers of bone turnover I: theoretical considerations and clinical use in osteoporosis. Am J Med. 1993;95:11S-16S.
33. Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993;91:1769-1774.
34. Diaz Diego EM, Diaz Martin MA, de la Piedra C, Rapado A. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. Horm Metabol Res. 1995;27:151-154.
35. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res. 1992;7:1243-1250.
36. Charles P, Mosekilde L, Risteli L, et al. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner. 1994;24:81-94.
37. Eriksen EF, Charles P, Melsen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993;8:127-132.
38. Eyre DR. New biomarkers of bone resorption. J Clin Endocrinol Metab. 1992;74:470A-470C.
39. Seyedin SM, Kung VT, Daniloff YN, et al. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res. 1993;8:635-642.
40. Robins SP, Woitge H, Hesley R, et al. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 1994;9:1643-1649.
41. Urena P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res. 1995;10:932-939.
42. Schlemmer A, Hassager C, Delmas PD, Christiansen C. Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy. Clin Endocrinol (Oxf). 1994;40:777-782.
43. Bettica P, Taylor AK, Talbot J, et al. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1996;81:542-546.
44. Eastell R, Robins SP, Colwell T, et al. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int. 1993;3:255-260.
45. Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res. 1993;8:881-889.
46. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 1995;17:383-390.
47. Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int. 1996;59:6-11.
48. Overgaard K, Christiansen C. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif Tissue Int. 1996;59:12-16.
49. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-152.
50. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 1994;9:135-142.
51. Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest. 1993;91:1138-1148.
52. Seibel MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab. 1992;74:481-486.
53. Garnero P, Vassy V, Bertholin A, et al. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab. 1994;78:955-959.
54. Stepan JJ, Limanova Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner. 1992;17:377-388.
55. Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab. 1991;72:1189-1194.
56. Li F, Iqbal J, Wassif W, et al. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int. 1994;55:90-93.
57. Mazzaferro S, Pasquali M, Ballant P, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant. 1995;10:52-58.
58. Lopez Gavilanes E, Gonzalez Parra E, de la Piedra C, et al. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Miner Electrolyte Metab. 1994;20:259-264.
59. Rubini G, Anelli F, Correale M, et al. Renal osteodystrophy with hyperparathyroidism: the diagnostic value of intact parathormone, alkaline phosphatase, osteocalcin and procollagen. J Nucl Biol Med. 1994;38:489-494.
60. Niwa T, Shiobara K, Hamada T, et al. Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta. 1995;235:33-40.
61. Iwasaki T. Effect of glucocorticoids on bone GIa protein values - BGP as a good marker of osteoporosis. Acta Paediatr Jpn. 1991;33:310-316.
62. Kerstjens HA, Postma DS, van Doormaal JJ, et al. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax. 1994;49:652-656.
63. Sorva R, Turpeinen M, Juntunen-Backman K, et al. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol. 1992;90:808-815.
64. Jennings BH, Andersson KE, Johansson SA. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol. 1991;40:77-82.
65. Pecherstorfer M, Zimmer-Roth I, Schilling T, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80:97-103.
66. Reale MG, Santini D, Marchei GG, et al. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer. Int J Biol Markers. 1995;10:42-46.
67. Desoize B, Amico S, Larbre H, et al. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma. Clin Biochem. 1991;24:443-446.
68. Francini G, Gonnelli S, Petrioli R, et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev. 1993;2:125-129.
69. Piovesan A, Berruti A, Osella G, et al. Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases. Int J Biol Markers. 1994;9:243-246.
70. Wada S, Katayama Y, Yasutomo Y, et al. Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy. Intern Med. 1993;32:611-618.
71. Conigrave AD, Jiang L. Ca(2+)-mobilizing receptors for ATP and UTP. Cell Calc. 1995;17:111-119.
72. Arai Y, Takeuchi H, Oishi K, Yoshida O. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate. 1992;20:169-177.